# US 2026/0216109 A1 · Treatment of skin disorders with short chain fatty acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216109 A1
- Document ID: US20260216109A1
- Status: Published application
- Kind: A1
- Application number: 19/147,069
- Filed: 2024-01-08
- Published: 2026-07-30
- Earliest claimed: 2023-01-11
- Assignees: Temple University of the Commonwealth System of Higher Education
- Applicants: Temple University-Of The Commonwealth System of Higher Education
- Inventors: Alla Arzumanyan; Ira Spector; Mark A. Feitelson
- Web page: https://patentgrep.com/patent/US20260216109A1

## CPC

- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/06: Antipsoriatics
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure describes methods of treating a condition comprising administering a pharmaceutical composition comprising at least one short chain fatty acid (SCFA). The disclosed methods can be used to treat a skin disorder or an autoimmune disorder.

## Claims

### Claim 1

A method of treating a condition, the method comprising:
a. administering a first pharmaceutical composition to a subject in need thereof, wherein the first pharmaceutical composition comprises a therapeutically-effective amount of a compound that is a short chain fatty acid or a pharmaceutically-acceptable salt thereof; and
b. administering a second pharmaceutical composition to the subject, wherein the second pharmaceutical composition comprises a therapeutically-effective amount of a phosphodiesterase-4 (PDE4) inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the condition is a skin disorder.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the condition is psoriasis.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the condition is an autoimmune disorder.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the short chain fatty acid is butyric acid.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the short chain fatty acid is propionic acid.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the compound is butyric acid or a pharmaceutically-acceptable salt thereof, and wherein the first pharmaceutical composition further comprises an additional short chain fatty acid or a pharmaceutically-acceptable salt thereof, wherein the additional short chain fatty acid is propionic acid or a pharmaceutically-acceptable salt thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the PDE4 inhibitor is Apremilast.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the therapeutically-effective amount of the PDE4 inhibitor is from about 10 mg to about 15 mg.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the first pharmaceutical composition further comprises vitamin D3 in an amount of from about 50 IU to about 200 IU.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the first pharmaceutical composition is formulated for oral administration.

### Claim 12

A method of treating a condition, the method comprising administering to a subject in need thereof a therapeutically-effective amount of a first pharmaceutical composition comprising at least one SCFA and a reduced amount of a second therapy, wherein the reduced amount of the second therapy is therapeutically effective for treating the condition in combination with the therapeutically-effective amount of the first pharmaceutical composition comprising at least one SCFA, and wherein the reduced amount of the second therapy is less than an amount of the second therapy that is therapeutically effective for the condition in absence of the therapeutically-effective amount of the first pharmaceutical composition comprising at least one SCFA.

### Claim 13 (depends on 12)

The method of claim 12, wherein the condition is a skin disorder.

### Claim 14 (depends on 12, 13)

The method of claim 12 or 13, wherein the condition is psoriasis.

### Claim 15 (depends on 12, 13, 14)

The method of any one of claims 12-14, wherein the condition is an autoimmune disorder.

### Claim 16 (depends on 12, 13, 14, 15)

The method of any one of claims 12-15, wherein the first pharmaceutical composition comprises butyric acid or a pharmaceutically-acceptable salt thereof.

### Claim 17 (depends on 12, 13, 14, 15, 16)

The method of any one of claims 12-16, wherein the first pharmaceutical composition comprises propionic acid or a pharmaceutically-acceptable salt thereof.

### Claim 18 (depends on 12, 13, 14, 15, 16, 17)

The method of any one of claims 12-17, wherein the first pharmaceutical composition comprises at least two SCFAs.

### Claim 19 (depends on 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 12-18, wherein the first pharmaceutical composition comprises butyric acid or a pharmaceutically-acceptable salt thereof and propionic acid or a pharmaceutically-acceptable salt thereof.

### Claim 20 (depends on 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 12-19, wherein the first pharmaceutical composition comprises an inorganic magnesium salt.

### Claim 21 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 12-20, wherein the first pharmaceutical composition comprises Vitamin D3.

### Claim 22 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 12-21, wherein the second therapy comprises a PDE4 inhibitor.

### Claim 23 (depends on 22)

The method of claim 22, wherein the PDE4 inhibitor is Apremilast.

### Claim 24 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 12-23, wherein the second therapy exhibits synergy with the first pharmaceutical composition.

### Claim 25 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 12-24, wherein the reduced amount of the second therapy comprises administering a reduced dosage of the second therapy to the subject.

### Claim 26 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 12-25, wherein the reduced amount of the second therapy comprises administering the second therapy to the subject at a reduced frequency.

### Claim 27 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 12-26, wherein the reduced amount of the second therapy comprises administering a reduced dosage of the second therapy to the subject at a reduced frequency.

### Claim 28 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 12-27, wherein the treating comprises causing reduction of a psoriatic lesion in the subject.

### Claim 29 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 12-28, wherein the treating comprises causing disappearance of a psoriatic lesion in the subject.
